Researchers recommend the biological safety cabinet be used whenever possible to compound parenteral products in a clinical setting.
List view / Grid view
Lynparza with abiraterone is the first PARP inhibitor to demonstrate clinical benefit in combination with a hormonal agent in this setting.
All five pre-symptomatic babies with spinal muscular atrophy (SMA) were able to swallow and feed orally after 12 months of treatment.
The European PRISMAP consortium will provide access to novel radioisotopes for medical research and promote the development of new radio-medicinal products.
The US FDA amended the emergency use authorisation to allow for a Comirnaty booster dose in individuals at high-risk for COVID-19.
A microneedle patch, which can be stored for >30 days at room temperature, safely delivered a DNA-based COVID-19 vaccine in mice.
Veklury (remdesivir) significantly reduced the risk of COVID-19 related hospitalisation and death in high-risk patients in Phase III study.
AstraZeneca will partner with VaxEquity for the discovery and development of a self-amplifying RNA (saRNA) therapeutics platform.
The Arctos Medical acquisition will expand Novarits’ optogenetics portfolio to bring gene therapies to patients with severe vision loss.
Johnson & Johnson announced Phase III data demonstrating effective COVID-19 protection and an increase in protection with a booster dose.
The next-generation active pharmaceutical ingredient manufacturing facility should meet the needs for AstraZeneca’s new medicines pipeline.
Xtandi reduced the risk of death by 34 percent in men with metastatic hormone sensitive prostate cancer in a Phase III study.
GSK announced multi-million renewable energy investment and low carbon inhaler programme in run-up to New York Climate Week.
Positive results from pivotal trial show that the COVID-19 vaccine Comirnaty is safe and effective in children aged five to 11 years old.
Roughly 17.6 percent of patients treated with Imfinzi plus chemotherapy were alive at three years, versus 5.8 percent of chemotherapy patients.